{"url_path":"/sec/revb/8-k/2026-07-13/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-13","source_url":"https://www.sec.gov/Archives/edgar/data/1810560/0001193125-26-302008-index.html","accession_number":"0001193125-26-302008","cik":"0001810560","ticker":"REVB","issuer_name":"REVELATION BIOSCIENCES, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1810560/0001193125-26-302008-index.html","primary_entity_key":"0001810560","primary_entity_name":"REVELATION BIOSCIENCES, INC."},"word_count":125,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n \n\n(d) Exhibits.\n\n \n\n \n\n \n\n \n\nExhibit No.\n\n \n\nDescription\n\n3.1\n\n \n\n[Certificate of Designation of Series B Junior Participating Preferred Stock of Revelation Biosciences, Inc.](revb-ex3_1.htm)\n\n4.1\n\n \n\n[Rights Agreement, dated as of July 10, 2026, between Revelation Biosciences, Inc. and Continental Stock and Transfer & Trust Co., as Rights Agent](revb-ex4_1.htm)\n\n99.1\n\n \n\n[Press Release, dated July 10, 2026](revb-ex99_1.htm)\n\n104\n\n \n\nCover Page Interactive Data File (embedded with the Inline XBRL document)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\n \n\nREVELATION BIOSCIENCES, INC.\n\n \n\n \n\n \n\nDate: July 13, 2026\n\nBy:\n\n/s/ Chester S. Zygmont, III\n\n \n\n \n\nChester S. Zygmont, III\nChief Financial Officer\n(principal financial and accounting officer)"}